Anaplastic lymphoma kinase (ALK) belongs to the family of tyrosine kinases and is regarded as a potential target for the treatment of neuroblastomas as ALK gene mutations and overexpression is frequently observed in neuroblastoma patients. This evidence concerns the gene ALK and neuroblastoma.